<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>: iStockAnalyst.com  Symbols Feed</title>
    <link>http://www.istockanalyst.com</link>
    <description>Custom RSS Feed</description>
    <generator>http://www.iStockAnalyst.com</generator>
    <pubDate>Mon, 09 Nov 2009 00:23:14 GMT</pubDate>
    <language>en</language>
    <ttl>30</ttl>
    <item>
      <title>Biostar Raises $3.6 Million</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3614366</guid>
      <description><![CDATA[Biostar Pharmaceuticals has completed a private placement that raised $3.6 million in new capital. Biostar will use the proceeds to complete its new raw materials processing facility. By taking its raw material production in house, Biostar will lower costs and ensure its product quality. Biostar plans to sell excess raw materials to other pharmaceutical companies in the Shaanxi province.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3614366>[More...]</a>]]></description>
      <pubDate>Fri, 06 Nov 2009 17:26:18 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BSPM</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3614366</link>
    </item>
    <item>
      <title>Bulls Back On Track?</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3614255</guid>
      <description><![CDATA[Good morning. With chants of &quot;Dow 10K… Dow 10K&quot; once again rising from the streets at the corner of Broad and Wall yesterday, it is easy to believe that the bulls are back on track and that we'll soon be looking at new highs for the stock market. And when reviewing the data inputs to yesterday's 204 point romp, it is also easy to don the Dow10K hat once again and join in on the celebration.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3614255>[More...]</a>]]></description>
      <pubDate>Fri, 06 Nov 2009 16:21:18 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CSCO</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3614255</link>
    </item>
    <item>
      <title>Ford's Main Problem: The UAW's Crippling Job Classifications And Work Rules</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3614051</guid>
      <description><![CDATA[Ford's 2,215 page 2007 master contract with the UAW 
1941 UAW-Ford contract<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3614051>[More...]</a>]]></description>
      <pubDate>Fri, 06 Nov 2009 13:52:50 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">F</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3614051</link>
    </item>
    <item>
      <title>Your Kind of Day?</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3611831</guid>
      <description><![CDATA[As a rule, I try not to read too terribly much into a &quot;Fed Day&quot; as there is usually a big batch of volatility that may or may not mean much of anything come the dawn of the next day. Maybe, it's just me. Or maybe there are others that find themselves inclined to simply stand aside and watch the nuttiness from the sidelines on &quot;Fed Days.&quot; But in any event, the volatility after a Fed announcement, while fun to watch, may not be telling as to what to expect in the future.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3611831>[More...]</a>]]></description>
      <pubDate>Thu, 05 Nov 2009 19:06:48 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CSCO</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TGT</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3611831</link>
    </item>
    <item>
      <title>The Dollar-Proof Portfolio</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3611744</guid>
      <description><![CDATA[Don't put off this important piece of the financial-planning process.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3611744>[More...]</a>]]></description>
      <pubDate>Thu, 05 Nov 2009 17:31:14 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CEW</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GLD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">IEO</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MON</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">STPZ</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">UDN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">VEU</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">VSS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">VTI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">WIP</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3611744</link>
    </item>
    <item>
      <title>Dr. Doom vs. The Investment Biker</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3608914</guid>
      <description><![CDATA[Roubini versus Rogers. Let's recap the match to date. First, Nouriel Roubini gets in the ring by himself and starts shadow boxing. He warns that a &quot;wall of liquidity&quot; and &quot;the mother of all carry trades&quot; (via the dollar) are consorting to spark asset bubbles which could lead to another financial crisis.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3608914>[More...]</a>]]></description>
      <pubDate>Thu, 05 Nov 2009 01:36:39 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">PCU</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ROG</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3608914</link>
    </item>
    <item>
      <title>The Significance Of The IMF-RBI Gold Sales</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3608516</guid>
      <description><![CDATA[Much has been written in the last two days about the surprising purchase by the RBI (Reserve Bank of India) of some 200 tonnes of gold bullion, valued at about $6.7 billion, from the IMF (International Monetary Fund).

Is this really a significant event?<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3608516>[More...]</a>]]></description>
      <pubDate>Thu, 05 Nov 2009 00:36:48 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CYO</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">FIA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MDC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ROG</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3608516</link>
    </item>
    <item>
      <title>What Investors Should Look for In Today’s Fed Statement</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3605772</guid>
      <description><![CDATA[In its continuing efforts to nurture the fragile economic recovery, the U.S. Federal Reserve is widely expected to leave interest rates at record lows when it concludes its meeting today (Wednesday).<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3605772>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 13:04:24 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BCS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ING</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3605772</link>
    </item>
    <item>
      <title>Are Discount Brokers Shares Worth Owning?</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3604683</guid>
      <description><![CDATA[The third quarter was a favorable one for the longs. Except for a few short-lived, minor pullbacks stock prices moved higher through the quarter. Stock price volatility declined, takeover activity rose, and risk appetite improved to help the S&amp;P gain 15%.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3604683>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 01:28:03 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AMTD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ETFC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SCHB</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3604683</link>
    </item>
    <item>
      <title>Technology Rises And Buying Facebook</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3601987</guid>
      <description><![CDATA[Technology stocks have done well this year. The Technology Select Sector SPDR (XLK) bottomed out in March and by late October was up more than 60%.&#160;&#160; Tech has performed better than any other sector year-to-date – up 33.7% as of Friday’s close.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3601987>[More...]</a>]]></description>
      <pubDate>Tue, 03 Nov 2009 16:54:11 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AMZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">EBAY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GOOG</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3601987</link>
    </item>
    <item>
      <title>Targacept has profit in quarter: Large milestone payment by AstraZeneca credited for first profit in almost three years</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3613879</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Nov. 6--Targacept Inc. posted its first quarterly profit in nearly three years yesterday, bolstered in large part by a $10 million milestone payment by AstraZeneca PLC. &lt;/li&gt;&lt;li&gt;Targacept, based in Piedmont Triad Research Park in Winston-Salem, is developing drugs based on nicotine research to treat diseases of the central nervous system. &lt;/li&gt;&lt;li&gt;The payment was the result of Targacept's research in adult attention deficit/hyperactivity disorder involving its AZD3480 drug compound, also known as TC-1734.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3613879>[More...]</a>]]></description>
      <pubDate>Fri, 06 Nov 2009 11:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TRGT</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3613879</link>
    </item>
    <item>
      <title>Auditor: Canada disaster planning is poor</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3607165</guid>
      <description><![CDATA[Auditor: Canada disaster planning is poor<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3607165>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 15:07:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3607165</link>
    </item>
    <item>
      <title>Vaccine-short Canada exporting 'surplus'</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3607404</guid>
      <description><![CDATA[Vaccine-short Canada exporting 'surplus'<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3607404>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 12:06:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3607404</link>
    </item>
    <item>
      <title>Largest malaria vaccine trial under way</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3602457</guid>
      <description><![CDATA[Largest malaria vaccine trial under way<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3602457>[More...]</a>]]></description>
      <pubDate>Tue, 03 Nov 2009 15:03:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3602457</link>
    </item>
    <item>
      <title>Business Highlights</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3599839</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;3 strong economic reports lift recovery hopes&lt;/li&gt;&lt;li&gt;WASHINGTON (AP) - Hopes for the fledgling economic recovery got a boost Monday from better-than-expected news on manufacturing, construction and contracts to buy homes.&lt;/li&gt;&lt;li&gt;Construction spending rose a bigger-than-expected a 0.8 percent in September, while the National Association of Realtors said the volume of signed contracts to buy previously occupied homes rose 6.1 percent in September to a reading of 110.1.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3599839>[More...]</a>]]></description>
      <pubDate>Mon, 02 Nov 2009 22:47:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BDK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CIT</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">HUM</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SWK</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3599839</link>
    </item>
    <item>
      <title>Canada's H1N1 flu vaccine running short</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3594381</guid>
      <description><![CDATA[Canada's H1N1 flu vaccine running short<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3594381>[More...]</a>]]></description>
      <pubDate>Fri, 30 Oct 2009 12:24:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3594381</link>
    </item>
    <item>
      <title>GlaxoSmithKline third quarter profit up 11 percent</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3586499</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;LONDON - GlaxoSmithKline PLC, the world's second largest drug maker by revenue, posted Wednesday an 11 percent rise in third quarter earnings on the back of strong sales of the flu drug Relenza and forecast an even bigger boost from its swine flu vaccines in the final quarter of the year.&lt;/li&gt;&lt;li&gt;London-based Glaxo reported net profit of 1.44 billion pounds ($2.35 billion) for the three months to Sept. 30, compared to 1.29 billion pounds a year ago.&lt;/li&gt;&lt;li&gt;Glaxo, which has been hit by rising competition from generic versions of its previously patented drugs, is expected to receive an earnings windfall from products dashed out in response to the H1N1 flu virus.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3586499>[More...]</a>]]></description>
      <pubDate>Wed, 28 Oct 2009 13:51:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3586499</link>
    </item>
    <item>
      <title>FDA OK's new leukemia treatment</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3582472</guid>
      <description><![CDATA[FDA OK's new leukemia treatment<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3582472>[More...]</a>]]></description>
      <pubDate>Tue, 27 Oct 2009 11:18:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3582472</link>
    </item>
    <item>
      <title>Evening Standard, London, Market Report Column</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3576618</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Oct. 23--Shares on the London stock market soared while the pound slumped  against the dollar as the UK economy continued to reel against the worst  recession on record. &lt;/li&gt;&lt;li&gt;That was the conclusion of financial markets on learning the shock news  that the UK economy continued shrinking during the third quarter. &lt;/li&gt;&lt;li&gt;The move may confound the man in the street, but dealers say the  Government will now have to continue with its quantitative easing programme  and much of that money will find its way back into the stock market as  investors look for better returns.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3576618>[More...]</a>]]></description>
      <pubDate>Fri, 23 Oct 2009 23:48:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AAUK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BHP</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BP</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BSY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">KAZ</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">NWS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">VOD</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3576618</link>
    </item>
    <item>
      <title>Schering-Plough Shares Hit Premerger Bump -- Fails Expectations, but Merck Deal Encouraging</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3576367</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Schering-Plough Corp. missed Wall Street expectations in the third quarter with sales and profit figures lower than in the same quarter last year.&lt;/li&gt;&lt;li&gt;The drugmaker, which soon will become part of much-larger Merck &amp; Co., reported revenues of $4.49 billion, or 29 cents per share, in the third quarter, down 2 percent from $4.57 billion last year.&lt;/li&gt;&lt;li&gt;But the bad news couldn't overshadow the company's planned merger with Merck .&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3576367>[More...]</a>]]></description>
      <pubDate>Fri, 23 Oct 2009 21:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3576367</link>
    </item>
    <item>
      <title>Merck and Schering-Plough to Complete Merger Today</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3601769</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Merck &amp; Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE:   SGP) today announced that they will complete their merger shortly   after 4:00PM ET today. &lt;/li&gt;&lt;li&gt;As previously announced, Schering-Plough   will change its name to Merck and its common stock will trade under the   ticker symbol &quot;MRK&quot; on the New York Stock Exchange.&lt;/li&gt;&lt;li&gt;The following factors, among others, could cause actual results to   differ from those set forth in the forward-looking statements: the   possibility that the expected synergies from the merger of Merck and   Schering-Plough will not be realized, or will not be realized within the   expected time period, due to, among other things, the impact of   pharmaceutical industry regulation and pending legislation that could   affect the pharmaceutical industry; the risk that the businesses will   not be integrated successfully; disruption from the merger making it   more difficult to maintain business and operational relationships;   Merck's ability to accurately predict future market conditions;   dependence on the effectiveness of Merck's patents and other protections   for innovative products; the risk of new and changing regulation and   health policies in the U.S. and internationally and the exposure to   litigation and/or regulatory actions.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3601769>[More...]</a>]]></description>
      <pubDate>Tue, 03 Nov 2009 15:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3601769</link>
    </item>
    <item>
      <title>Ligand to Acquire Metabasis for Cash and Contingent Value Rights</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3582276</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Metabasis   Therapeutics, Inc. (NASDAQ: MBRX) announced today they have entered into   a definitive merger agreement under which Ligand will acquire all of the   outstanding shares of Metabasis.&lt;/li&gt;&lt;li&gt;The CVRs will entitle   Metabasis stockholders to cash payments as frequently as every six   months as cash is received by Ligand from proceeds from the sale or   partnering of any of the Metabasis drug development programs, among   other triggering events. &lt;/li&gt;&lt;li&gt;Such forward-looking statements   include, but are not limited to, the expected timing of closing the   merger, statements about the benefits of the transaction between Ligand   and Metabasis, including future financial and operating results and   revenue potential, the expected effect of the merger on Ligand's   operating cash burn rate, the possibility of payments being made under   the CVR agreements, the combined entity's plans, objectives,   expectations and intentions and other statements that are not historical   facts.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3582276>[More...]</a>]]></description>
      <pubDate>Tue, 27 Oct 2009 11:48:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">LGND</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MBRX</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3582276</link>
    </item>
    <item>
      <title>RidgewaterEquity.Com Free Fundamental Sector &amp;Amp; Market Research on OLN, LXK, SGP, MMM, LYG and STSI</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3578842</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;RidgewaterEquity.com inspires to bring the best from the internet under one roof, providing you with a one click option to view what the market, researchers and financial pundits worldwide have to say about any particular large cap stocks in any given financial environment. &lt;/li&gt;&lt;li&gt;Once you sign up as a free member you will have free unlimited access to all our reports, research tools and more.&lt;/li&gt;&lt;li&gt;We have recently begun in-depth analysis of the following equities &amp;amp; their respective sectors:&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3578842>[More...]</a>]]></description>
      <pubDate>Mon, 26 Oct 2009 12:04:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">LXK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">LYG</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MMM</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">OLN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">STSI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3578842</link>
    </item>
    <item>
      <title>Procter &amp;Amp; Gamble Co. Up 13% Since Added to Galtstock Long Portfolio</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3576305</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Subscribers to galtstock.com &quot;Long-Term Portfolio&quot; service (membership) invest in solid long-term holdings. &lt;/li&gt;&lt;li&gt;Other stocks in our portfolio are Procter &amp;amp; Gamble (NYSE: PG), Coca-Cola (NYSE: KO), GlaxoSmithKline (NYSE: GSK), and McDonald's Corp. (NYSE: MCD).&lt;/li&gt;&lt;li&gt;To sign up for Galt's Long-Term Portfolio service, please visit the website at http://www.galtstock.com/Long-Term-Portfolio.html with secure check out.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3576305>[More...]</a>]]></description>
      <pubDate>Fri, 23 Oct 2009 21:07:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">KO</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MCD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PG</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3576305</link>
    </item>
    <item>
      <title>Bristol-Myers Squibb Achieves Strong Sales, Earnings Performance in Third Quarter</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3571548</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Bristol-Myers   Squibb Company (NYSE:BMY) today reported strong sales and earnings   growth for the third quarter 2009.&lt;/li&gt;&lt;li&gt;&quot;The performance in the third quarter of 2009 clearly shows the results   of our outstanding business performance, disciplined financial   management and overall strategic execution,&quot; said James   M. Cornelius, chairman and chief executive officer. &lt;/li&gt;&lt;li&gt;Third Quarter Performance                                                                                                                2009        2008        Change   Net Sales                                           $  5,487    $  5,254    4%       Net Earnings from Continuing Operations             $  966      $  588      64%      GAAP Diluted EPS from Continuing Operations            0.48        0.29     66%      Non-GAAP Diluted EPS from Continuing Operations        0.52        0.45     16%      ($ amounts in millions, except per share amounts)&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3571548>[More...]</a>]]></description>
      <pubDate>Thu, 22 Oct 2009 11:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BMY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MJN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3571548</link>
    </item>
    <item>
      <title>Mead Johnson Reports Solid Third Quarter Results; Narrows Full-Year 2009 Guidance to Top End of Range</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3571551</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Mead Johnson Nutrition Company (NYSE: MJN) announced today its financial   results for the third quarter ended Sept. 30, 2009, including:&lt;/li&gt;&lt;li&gt;GAAP earnings of $0.48 per diluted share, down from $0.61 a year ago,   reflecting the impact of higher interest expense and shares   outstanding in 2009.&lt;/li&gt;&lt;li&gt;Third Quarter GAAP Results Net sales for the third quarter   of 2009 totaled $699.8 million, down 6 percent from $742.8 million a   year-ago.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3571551>[More...]</a>]]></description>
      <pubDate>Thu, 22 Oct 2009 11:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BMY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MJN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3571551</link>
    </item>
    <item>
      <title>Fitch: Credit Quality Stable for Global Pharma Sector With Increase of New Drug Approvals in 2Q'09</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3473471</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;According to Fitch Ratings' new Global Pharmaceutical R&amp;D Pipeline,   credit quality remains stable for the global pharmaceutical sector while   large firms modestly grew revenues in the second quarter despite   economic turbulence. &lt;/li&gt;&lt;li&gt;The second quarter proved to be busy for the drug agencies as eight new   medicines were approved by the U.S. Food &amp; Drug Administration (FDA) and   seven were cleared for marketing by the European Medicines Agency   (EMEA). &lt;/li&gt;&lt;li&gt;Moreover, drug developers covered in the report may receive   regulatory clearances for marketing nearly 20 new molecular entities   (NMEs) in the U.S. or Europe prior to the end of 2009.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3473471>[More...]</a>]]></description>
      <pubDate>Fri, 11 Sep 2009 13:47:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3473471</link>
    </item>
    <item>
      <title>Bristol-Myers Squibb Announces Dividend</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3468491</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;The Board of Directors of Bristol-Myers   Squibb Company (NYSE: BMY) declared a quarterly dividend of   thirty-one cents ($0.31) per share on the $.10 par value Common Stock of   the corporation. &lt;/li&gt;&lt;li&gt;The quarterly dividend will be payable on November 2,   2009 to stockholders of record at the close of business on October 2,   2009.&lt;/li&gt;&lt;li&gt;The Directors also declared a quarterly dividend of fifty cents ($0.50)   per share on the $2.00 Convertible Preferred Stock of the corporation,   payable December 1, 2009 to stockholders of record at the close of   business on November 6, 2009.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3468491>[More...]</a>]]></description>
      <pubDate>Wed, 09 Sep 2009 20:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BMY</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3468491</link>
    </item>
    <item>
      <title>Pronova BioPharma Receives 2009 Frost &amp;Amp; Sullivan Award for Excellence in Financial &amp;Amp; Risk Management</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3463623</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;8 September 2009, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) (&quot;Pronova BioPharma&quot; or &quot;the company&quot;) today announces that it has been awarded the 2009 Frost &amp;amp; Sullivan Excellence in Financial &amp;amp; Risk Management Award in the Global Heart Health Ingredients market for its lead product Omacor(R)/LovazaTM, the first and only EU- and FDA-approved omega-3 derived prescription drug.&lt;/li&gt;&lt;li&gt;The Frost &amp;amp; Sullivan Excellence in Financial &amp;amp; Risk Management Awards are presented annually to companies that demonstrate outstanding management of current market conditions, besides preparing for the future, above others within their respective industries.  &lt;/li&gt;&lt;li&gt;This award recognises Pronova BioPharma's excellent product quality and favourable customer opinions, continued strong customer demand for Omacor/Lovaza, innovation supporting next generation omega-3 derived products (through ongoing collaborations in indications such as heart failure, atrial fibrillation and cardiac disease in type II diabetic patients) and sound operational and financial risk management practices.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3463623>[More...]</a>]]></description>
      <pubDate>Tue, 08 Sep 2009 15:48:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3463623</link>
    </item>
    <item>
      <title>Frost &amp; Sullivan Global Heart Health Ingredients Excellence in Financial &amp; Risk Management Award Conferred on Pronova BioPharma</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3463175</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;LONDON, Sept. 8 /PRNewswire/ -- The 2009 Frost &amp; Sullivan Global Heart Health Ingredients Excellence in Financial &amp; Risk Management Award is presented to Pronova BioPharma ASA. &lt;/li&gt;&lt;li&gt;Pronova BioPharma has demonstrated excellence in financial management. &lt;/li&gt;&lt;li&gt;Pronova BioPharma's return on assets (ROA) improved from 16.8 per cent in 2007 to 34.5 per cent in 2008.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3463175>[More...]</a>]]></description>
      <pubDate>Tue, 08 Sep 2009 11:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3463175</link>
    </item>
    <item>
      <title>Form  4          MCGRATH EUGENE R          For: Nov 03 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3608279</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3608279>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 22:43:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3608279</link>
    </item>
    <item>
      <title>Form  4          Colligan Thomas J         For: Nov 03 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3608273</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3608273>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 22:41:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3608273</link>
    </item>
    <item>
      <title>Form  4          PEREZ ANTONIO M           For: Nov 03 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3608274</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3608274>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 22:41:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3608274</link>
    </item>
    <item>
      <title>Form  4          WEINBACH ARTHUR F         For: Nov 03 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3608270</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3608270>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 22:40:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3608270</link>
    </item>
    <item>
      <title>Form  4          Merck &amp; Co. Inc.          For: Nov 03  Filed by: STAHL JACK L (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3608269</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3608269>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 22:39:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3608269</link>
    </item>
    <item>
      <title>Form  4          SAUNDERS BRENT L          For: Nov 03 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3608266</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3608266>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 22:38:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3608266</link>
    </item>
    <item>
      <title>Form  4          Merck &amp; Co. Inc.          For: Nov 03  Filed by: TURNER KATHRYN C (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3608263</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3608263>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 22:37:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3608263</link>
    </item>
    <item>
      <title>Form  4          SABATINO THOMAS J JR      For: Nov 03 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3608260</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3608260>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 22:36:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3608260</link>
    </item>
    <item>
      <title>Form  4          VAN OORDT ROBERT FW       For: Nov 03 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3608257</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3608257>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 22:35:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3608257</link>
    </item>
    <item>
      <title>Form  4          Queisser Lori A.          For: Nov 03 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3608251</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3608251>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 22:34:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3608251</link>
    </item>
    <atom:link href="http://www.istockanalyst.com/widget/customsymbolfeed.aspx?symbols=BMY,GSK,ROG,SGP," rel="self" type="application/rss+xml" />
  </channel>
</rss>